morning, Ed. joining for today. thank us you, you thank everyone and Great, Good
our Acceleron a deep clinical regulatory So really of can the in see months. updates extremely exciting tremendous our and is areas. I’m the us superfamily three development near-term proud had area the as disease This TGF-beta expertise of across for an entire pipeline time number disease with you of of significant with the in across all and coming weeks teams. progress
with who require of adult Agency red MAA currently positive respectively, of blood and with filings, anemia transfusions anemia cell adult require red with treatment RS USFDA Beginning treatment transfusions. European beta-thalassemia myelodysplastic regular patients the the reviewing for luspatercept, the who and syndromes and BLA in cell the patients are are blood for and the Medicines in
XXXX. December for target first with of date beta-thalassemia of Acceleron granting indication, the of FDA review priority approval action medicine the away far our PDUFA Xth, from With not an the potential discovered
For of MDS targeted indication, action date the set has XXXX. a Xth, April the FDA
milestone organization and upon commercial Our luspatercept this report to pleased FDA for will available ready begin to am that I to making approval preparing has worked patients. hard be
In the both of are EU half deliver XXXX. applications in addition, indications the expected their decision second for on regulators in to
and We’ll to disorders closely in We Acceleron or bring believe toward with delivering eliminating to both these and red work forward continue this this by with significant Celgene, This partner, therapy potentially achievement blood to blood luspatercept step advance to agencies is for that patients our another decreasing huge approval. innovative a transfusion therapy benefit burden. cell the could collaboration patients.
looking are ASH on publicly available another a Meeting, forward accepted abstracts luspatercept on Key We to been clinical total and and are have productive of website. six now important ASH’s Annual Phase respectively, from presentations X trial. in beta-thalassemia, X and well BELIEVE MEDALIST and from MDS new as updated and as pivotal include ongoing interim Phase myelofibrosis results the analyses trials our
to of XXXX top with positive. independence cut some now in data response summarize through important analyses XX.X% achieve line in XX patients that the are The data Beginning the lower with updated with I’ll January who risk included these which MEDALIST, abstracts. enrolled in RS points patients treatment treated show XXXX. luspatercept blood cell the transfusion cut seen the data relative with May red week at rate XX.X% of
independence weeks eight defined median cell more of transfusion duration for this calculated least at and/or as So modified response. HI-E data we blood on benefit, abstract the red based cut, is clinical recent which
approximately the XX duration months. For clinical XX.X patients of was responding weeks to luspatercept, or median benefit
response had benefit, receiving that note, luspatercept multiple in to important cumulative placebo. patients the independence transfusion trial also periods clinical that superior MEDALIST most of is patients with of to the in and/or with erythroid durability achieving study It response
of the defined to of May equal any that weeks greater benefit discontinuation the units for red XXXX Median due first response to weeks transfusion duration cause XX episode, reduction abstract. XX% as time over trial than XX.X to responders key data clinical and as was any cut. of in to BELIEVE blood of Moving in the cell luspatercept
XX% of units weeks. response loss patients X.XX of and of over within average more period. saved receiving units responders transfusion cell with any luspatercept weeks red XX study luspatercept patients a was had blood the burden over than of or all the XX XX XX in units no The entire baseline units, number X.XX was for
concomitant the with receiving the associated ongoing ASH Lastly, our including in study those of in with luspatercept, anemia abstract for suggest meaningful activity interim included patients ruxolitinib. myelofibrosis patients results clinically
with cohorts X.X in XX% least grams increase of achieved luspatercept, or the non-transfusion-dependent deciliter. patients the combination ruxolitinib cohort hemoglobin with in at per of Notably, including treatment the XA X mean
transfusion-dependent patients over to XX% XB, or the or achieved independence or Also, cohort, group, cohort cell achieved baseline. a In XX compared consecutive weeks. in transfusion red within X XX% burden blood reduction patients XX% any transfusion XX of better this
alone. per cohorts luspatercept the trial or mean XX% to achieved non-transfusion-dependent at In of deciliter. X X.X with receiving treatment least X, patients grams for increase of Moving the patients cohort hemoglobin
X, XX% over weeks. XX patients trial or transfusion-dependent consecutive X of cohort any In independence achieved transfusion
studies results and minority at in to MDs safety, that X showed of a AEs X severity, which Looking consistent with and is grades were previous beta-thalassemia.
PULSAR study program is orphan and PAH sotatercept Phase patients. PAH controlled FDA which designation our evaluate like efficacy to focus placebo September. pulmonary and randomized trial drug on designed of received a move X to the from with in the double-blind, sotatercept, I’d that, safety our in With with to PULSAR
XXX sotatercept standard with milligrams A of of combination therapies. placebo kilogram randomized been total in sotatercept care kilogram of X.X of to receive per per have patients X.X or milligrams
and to in participants Phase primary treatment trial quarter XXXX. the results baseline from distance. The top trial a exploratory continue the is period, X-minute XXXX preliminary in Resistance, the changed our extension look in month We in to of the reporting SPECTRA from period. Following month line is will XX walk primary of trial trial in X forward endpoint baseline in be Vascular the results the key Pulmonary the from endpoint secondary in PULSAR eligible change first X
CMT. ACE-XXX in Charcot-Marie-Tooth with trial Disease turn our from now updates I’ll or to neuromuscular our program
Although where disorder for XXX,XXX treatments neurological CMT prevalence patients, the FDA with the there most exceeding US commonly CMT. are inherited no is
Part was to currently Phase We’re X which period, X by ACE-XXX assess efficacy of in conducting designed of safety patients, a study. randomized the to at and over trial, one followed open XX total X CMT our label X month treatment placebo a versus month one
such change disease-specific reporting test. muscle percent the We’ll line is XXXX. anticipate also with top We time in to fraction measured endpoint fat endpoints, of tests this reported from primary via outcomes. X secondary results first of total volume in function as in including as walking motor evaluating patient Part the be study MRI, The quarter
call over hand to the with our I’d financials. And to to review Kevin that, CFO like McLaughlin, the
